Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Erysipelas: recognition and management.

Jean-Marie Bonnetblanc1, Christophe Bédane

  • 1Department of Dermatology, CHRU Dupuytren, Limoges, France. jean-marie.bonnetblanc@chu-limoges.fr

American Journal of Clinical Dermatology
|March 12, 2003
PubMed
Summary

Erysipelas, a bacterial skin infection, typically presents with inflammation and is often caused by group A streptococci. Prompt diagnosis and treatment with antibiotics like penicillin G are crucial for managing this condition and preventing recurrence.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence and Mortality of Mucous Membrane Pemphigoid in France.

The British journal of dermatology·2026
Same author

Combination of Omalizumab and Dupilumab for the Treatment of Severe Bullous Pemphigoid: a Series of 6 Cases.

Acta dermato-venereologica·2025
Same author

Ustekinumab as a potential therapeutic agent in bullous pemphigoid: a biologic and clinical proof-of-concept study.

The British journal of dermatology·2025
Same author

Long-Term Efficacy and Safety of Rituximab in Patients With Pemphigus Foliaceus Compared With Pemphigus Vulgaris.

JAMA dermatology·2025
Same author

Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.

JAMA dermatology·2024
Same author

Efficacy and safety of dupilumab in bullous pemphigoid: a retrospective multicentric study of 36 patients.

The British journal of dermatology·2023

Area of Science:

  • Dermatology
  • Infectious Diseases
  • Microbiology

Background:

  • Erysipelas is an acute bacterial infection affecting the dermis and hypodermis, presenting as a distinct clinical form of cellulitis.
  • Group A streptococci are the primary causative agents, with streptococcal toxins likely contributing to the observed inflammation.
  • The leg is the most common site, characterized by sudden onset, erythema, edema, and well-defined margins; athlete's foot is a frequent entry point.

Purpose of the Study:

  • To define erysipelas as a specific clinical entity distinct from general cellulitis.
  • To highlight key clinical features, diagnostic considerations, and management strategies for erysipelas.
  • To emphasize the importance of identifying severity markers and potential complications.

Main Methods:

Related Experiment Videos

  • Clinical observation and characterization of erysipelas presentation.
  • Review of etiological factors, particularly group A streptococci and toxins.
  • Analysis of diagnostic challenges, differential diagnoses, and laboratory workup necessity.
  • Evaluation of treatment options and complication management.

Main Results:

  • Erysipelas typically presents with sudden onset, fever, localized erythema, and edema with sharp demarcation.
  • Group A streptococci are the main cause, and while diagnosis is primarily clinical, severity markers necessitate hospitalization.
  • Recurrence is a significant complication, and while generally sensitive to penicillin G, amoxicillin and macrolides are also effective.
  • Bed rest, leg elevation, and treatment of the entry portal are important supportive measures.

Conclusions:

  • Erysipelas should be recognized and studied as a distinct entity within bacterial skin infections.
  • Effective management involves prompt antibiotic therapy, supportive care, and addressing predisposing factors to prevent recurrence.
  • Further comparative studies are needed to optimize therapeutic strategies and cost-effectiveness.